Patent EP0039179A2 successfully refreshed from Google Patents.
← Back to Patent Explorer
US4727151A Expired / Lapsed US ⏱️ 0.0 years remaining

Labile quaternary ammonium salts as prodrugs

Assignee: Merck and Co Inc
•
Filing: 1978-11-22
•
Granted: 1988-02-23
•
Expires: 1998-11-22
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Labile quaternary ammonium salts of the following formula (I) and (II) are provided: <IMAGE> (I) <IMAGE> (II) wherein N represents a tertiary aliphatic amine; wherein N represents an unsaturated amine; wherein R represents a member selected from the group consisting of a hydrogen atom, a C1-C8 open chain or cyclo alkyl group, a C1-C8 alkoxyalkyl group, a C1-C8 acyloxyalkyl group, a C1-C8 haloalkyl group, a C1-C8 carboxyalkyl group, a C2-C8 alkenylphenyl group, an aryl group, and a substituted aryl group, whose substituents are selected from the group consisting of a halogen atom, an O-lower alkyl (C1-C4) group, an O-acyl group, a nitro group, a carboxyl group, and a carboethoxy group; wherein R1 which may be the same or different, represents any member defined by R above with the proviso that R1 cannot be a hydrogen atom; wherein X is -O- or -S-; and wherein Y represents a member selected from the group consisting of a halogen atom or any other organic or inorganic monovalent equivalent anion; with the further proviso that N and N, respectively cannot represent trimethylamine and pyridine or quinoline when R represents a hydrogen atom and R1 represents a methyl group or a phenyl group. The compounds described above are characterized by their extreme solubility and resistance to oxidation, dealkylation, and protonation prior to chemical and/or enzymatic hydrolysis. Upon chemical and/or enzymatic hydrolysis, these compounds will "cleave," thus releasing their active constituent or constituents, according to the following general scheme(s): <IMAGE> +TR <IMAGE> <IMAGE> +TR <IMAGE> In other words, the title compounds hydrolyze (chemically or enzymatically) releasing a tertiary amine or unsaturated amine derivative, an aldehyde, a carboxylic acid and a hydrogen halide (HX) per the above reaction scheme.

Inventors

  • 👤 Nicolae S. Bodor

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-04 08:44
CPC Classifications
C; C07; C07D; C07D249/00; C07D249/02; C07D249/08; C07D213/00; C07D213/02; C07D213/04; C07D213/60; C07D213/78; C07D213/79; C07D213/80; C07D213/81; C07D213/82; C07D231/00; C07D231/02; C07D231/10; C07D231/12; C07D233/00; C07D233/54; C07D233/56; C07D487/00; C07D487/02; C07D487/08

Claims Analysis

Total Claims: 5
Claim 1
Independent Claim 45 words
A labile quaternary ammonium salt being capable of cleavage upon chemical or enzymatic hydrolysis to deliver a pharmacologically active tertiary amine and having the structural formulas (I) ##STR310## wherein N.sup.⊕ -- is a pharmacologically active tertiary amine moiety selected from the group consisting of lidocaine;
Claim 2
Dependent Claim 45 words
A labile quaternary ammonium salt being capable of cleavage upon chemical or enzymatic hydrolysis to deliver a pharmacologically active tertiary amine and having the structural formulas (I) ##STR310## wherein N.sup.⊕ -- is a pharmacologically active tertiary amine moiety selected from the group consisting of lidocaine;
Claim 3
Dependent Claim 162 words
8-Dichloro-α-[dibutylaminomethyl]-2-[3',4'-dichlorophenyl]-4-quinolinemethyl-N,N-dimethyl glycinate; 3-[Dibutylamino]-1-[2,6-bis-trifluoromethylphenyl)-4-pyridyl]propanol-N,N-dimethylglycinate; N,N-Dimethyl-N'-phenyl-N'-(2-thienyl)-ethylenediammonium; β-Dimethylaminoethyl(p-chloro-α-methyl benzhydryl)ether; N-Ethylephedrine; 2-Diethylaminopropiophenone; (Bicyclohexyl)-1-carboxylic acid 2-(diethylamino)-ethyl ester; Diphenylthioacetic acid 5-(2-diethylaminoethyl)ester; 6-Dimethylamino-4,4-diphenyl-3-heptanone; chlorcyclizine; methapheniline; pyrathiazine; pyrilamine; chlorophenoxamine; clemastine; diphenylpyraline; doxylamine; phenindamine; cyclizine; etafedrine acetate; benzphetamine; phendimetrazine; cinnamedrine acetate; piperoxan; arecoline; physostigmine; adiphenine; dicylomine; piperidolate; thiphenamil; pipoxolan; tremorine; nicotine; cocaine; piperocaine; dibucaine; mepivacaine; pyrrocaine; fentanyl; benzydamine; methadone; propoxyphene; chlorpromazine; diazepam; or cotinine; R is hydrogen C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 alkoxyalkyl, C 1 -C 8 haloalkyl, C 6 -C 10 aryl or substituted C 6 -C 10 aryl whose substituents are selected from the group consisting of halogen, C 1 -C 4 alkoxy, nitro, carboxyl, and carboethoxy; R 1 which can be the same as or different from R, is any member of the group defined by R above, with he proviso that R 1 cannot be a hydrogen atom; X is --O-- or --S--; and Y is halogen or an equivalent nontoxic pharmaceutically acceptable organic or inorganic monovalent anion.
Claim 4
Dependent Claim 162 words
8-Dichloro-α-[dibutylaminomethyl]-2-[3',4'-dichlorophenyl]-4-quinolinemethyl-N,N-dimethyl glycinate; 3-[Dibutylamino]-1-[2,6-bis-trifluoromethylphenyl)-4-pyridyl]propanol-N,N-dimethylglycinate; N,N-Dimethyl-N'-phenyl-N'-(2-thienyl)-ethylenediammonium; β-Dimethylaminoethyl(p-chloro-α-methyl benzhydryl)ether; N-Ethylephedrine; 2-Diethylaminopropiophenone; (Bicyclohexyl)-1-carboxylic acid 2-(diethylamino)-ethyl ester; Diphenylthioacetic acid 5-(2-diethylaminoethyl)ester; 6-Dimethylamino-4,4-diphenyl-3-heptanone; chlorcyclizine; methapheniline; pyrathiazine; pyrilamine; chlorophenoxamine; clemastine; diphenylpyraline; doxylamine; phenindamine; cyclizine; etafedrine acetate; benzphetamine; phendimetrazine; cinnamedrine acetate; piperoxan; arecoline; physostigmine; adiphenine; dicylomine; piperidolate; thiphenamil; pipoxolan; tremorine; nicotine; cocaine; piperocaine; dibucaine; mepivacaine; pyrrocaine; fentanyl; benzydamine; methadone; propoxyphene; chlorpromazine; diazepam; or cotinine; R is hydrogen C 1 -C 8 alkyl, C 3 -C 8 cycloalkyl, C 2 -C 8 alkoxyalkyl, C 1 -C 8 haloalkyl, C 6 -C 10 aryl or substituted C 6 -C 10 aryl whose substituents are selected from the group consisting of halogen, C 1 -C 4 alkoxy, nitro, carboxyl, and carboethoxy; R 1 which can be the same as or different from R, is any member of the group defined by R above, with he proviso that R 1 cannot be a hydrogen atom; X is --O-- or --S--; and Y is halogen or an equivalent nontoxic pharmaceutically acceptable organic or inorganic monovalent anion.
Claim 5
Dependent Claim 56 words
The compound of claim 1 which is (a) ω-(Diethyl-benzoyloxymethyl-ammonium)-2,6-dimethylacetanilide chloride; (b) ω-(Diethyl-benzoyloxybenzoyl-ammonium)-2,6-dimethylacetanilide chloride; (c) ω-[Diethyl-(α-benzoyloxyethyl)-ammonium]-2,6-dimethylacetanilide chloride; (d) [6,8-Dichloro-α-[dibutylaminomethyl]-2-[3',4'-dichlorophenyl-4-quinolinemethyl-N]-benzoyloxymethyl-[N,N-dimethylglycinate chloride]; (e) [6,8-Dichloro-α-[dibutylaminomethyl]-2-[3',4'-dichlorophenyl]-4-quinolinemethyl-N]-[α-benzoyloxybenzyl]-[N,N-dimethylglycinate chloride]; (f) 3-[Dibutylamino]-1-[(2,6-bis-trifluoromethylphenyl)-4-pyridyl]propanol-N-benzoyloxymethyl-N,N-dimethylglycinate chloride; (g) 3-[Dibutylamino]-1-[(2,6-bis-trifluoromethylphenyl)-4-pyridyl]propanol-N-pivalyloxymethyl-N,N-dimethylglycinate chloride; (h) N,N-Dimethyl-N-hexanoyloxymethyl-N'-phenyl-N'-(2-thenyl)ethylenediammonium chloride; (i) β-Dimethylaminoethyl (p-chloro-α-methyl benzhydryl)ether-N-benzoyloxymethyl chloride; (j) N-Ethylephedrine (α-benzoyloxyethyl)chloride; (k) 2-Diethylaminopropiophenone (α-benzoyloxyethyl)chloride; (l) (Bicyclohexyl)-1-carboxylic acid 2-(diethylamino)-ethyl ester N-hexanoyloxymethyl chloride; (m) Diphenylthioacetic acid 5-(2-diethylaminoethyl)ester-N-thioacetyl chloride; (n) 6-Dimethylamino-4,4-diphenyl-3-heptanone-N-(p-toluyloxymethyl)chloride;

References Cited (Backward Citations)

US3873583A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1991-02-22 1991-08-24 1992-02-23 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1995-02-22 1995-08-24 1996-02-23 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1999-02-22 1999-08-24 2000-02-23 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag